<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01921322</url>
  </required_header>
  <id_info>
    <org_study_id>CEP270</org_study_id>
    <nct_id>NCT01921322</nct_id>
  </id_info>
  <brief_title>Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy</brief_title>
  <official_title>Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy for Hospitalized Patients in China With Type 2 Diabetes; Time to Target</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized (open label), multi-center and post-market study. The study
      is to compare effectiveness of sensor-augmented pump (SAP) therapy versus multiple daily
      injection (MDI) therapy in hospitalized patients with insulin treating type 2 diabetes in
      China
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:

      To compare the length of time to achieve target glucose range using Self-Monitoring Blood
      Glucose (SMBG), as reference method, with the 722 Paradigm Real-Time insulin pump versus MDI

      Secondary Objectives:

      To compare glycemic variability (using CGM as reference method) with the 722 Paradigm
      Real-Time insulin pump versus MDI

      This is a prospective, randomized (open label), multi-center study. The clinical study staff
      will conduct screening tests according to inclusion/exclusion criteria in order to verify the
      subject's eligibility for the study.

      Inpatient Period A patient is admitted into hospital for treatment of diabetes

      Randomization

      Subjects are randomized (at a 1:1 ratio) to group A or B in the study database. A total of 80
      subjects will be randomized into 2 study groups:

        -  Group A will wear 722 Paradigm Real-Time System (treated with 24h per day insulin
           infusion)

        -  Group B will be on MDI and wear the CGMS-Gold (treated with 4 insulin injections).

      It is anticipated that the total duration for the study will be within one year from site
      initiation to finalization of all data entry and monitoring.

      Each subject will participate in the study approximately 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects randomly assigned to undergo treatment using either the Paradigm 722 insulin pump or multiple daily insulin injections.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Target</measure>
    <time_frame>Up to 14 days in hospital</time_frame>
    <description>length of time to achieve target glucose range using Self-Monitoring Blood Glucose (SMBG), as reference method, with the 722 Paradigm Real-Time insulin pump versus Multiple Daily Injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic Variability</measure>
    <time_frame>Up to 14 days in hospital</time_frame>
    <description>Glycemic variability (mean amplitude glycemic excursion) using CGM as reference method</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Pump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple daily insulin injections used for treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pump</intervention_name>
    <description>722 Paradigm Real-Time System</description>
    <arm_group_label>Pump</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CGMS Gold</intervention_name>
    <description>Device used to collect retrospective sensor data, blinded to the subjects, to compare to the treatment arm</description>
    <arm_group_label>MDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 18 to 65 years old at time of screening

          2. A clinical diagnosis of type 2 diabetes &gt; 6 months prior to the screening as
             determined by the Investigator,

          3. Treating with insulin at least one injection per day prior to participate in the study

          4. Glycosylated hemoglobin (A1C) &gt; 8% at screening

          5. Subject needs to be hospitalized to receive treatment for glucose management according
             to Endocrinologists' discretion

          6. Subject is willing to follow protocol and underdo all study procedures

          7. Subject is willing and able to provide informed written consent personally or by legal
             proxy

        Exclusion Criteria:

          1. Subject has known hypersensitivity to insulin or insulin infusion set

          2. Subject has been treated with drugs with a known effect on BG within 8 weeks before
             enrollment other than diabetes medications such as insulin or oral agents.

          3. random blood glucose is above 33 mmol/L

          4. Subject is currently using real time CGM therapy prior to screening

          5. Subject is currently using insulin pump therapy prior to screening

          6. Female subject who is pregnant, or plans to become pregnant during the course of the
             study

          7. Patients who are critically ill that must go to intensive critical care unit per
             Investigator discretion

          8. Subject has any systemic disease or medical condition found on the screening tests
             that may interfere with the safety of the patient and efficacy of the study treatment,
             in the opinion of the Investigator, may preclude him/her from participating in the
             study. The following includes, but not limited to, those conditions:

               -  Female subject has a positive serum pregnancy screening test

               -  Subject has visually impaired or disability limits the use of RT-CGM.

               -  Subject has any unresolved adverse skin condition in the area of sensor placement
                  or device replacement (e.g., psoriasis, rash, Staphylococcus infection)

               -  Subject has disease with a known effect on BG such as Active Graves' disease

               -  Subject has a history of alcohol abuse

          9. Any other condition, which may not be suitable for the study at physician's
             discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2013</study_first_submitted>
  <study_first_submitted_qc>August 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2013</study_first_posted>
  <results_first_submitted>May 12, 2017</results_first_submitted>
  <results_first_submitted_qc>June 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2017</results_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pump</title>
          <description>Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring</description>
        </group>
        <group group_id="P2">
          <title>Multiple Daily Injections</title>
          <description>Multiple daily insulin injections used for treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Amoung the study completers, four met the target range on or before the first day and one subjects blinded CGM data was lost due to removal of the devices battery. The five subjects were excluded from the final analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Pump</title>
          <description>Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring</description>
        </group>
        <group group_id="B2">
          <title>Multiple Daily Injections</title>
          <description>Multiple daily insulin injections used for treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="10.2"/>
                    <measurement group_id="B2" value="49" spread="9.6"/>
                    <measurement group_id="B3" value="50" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167" spread="8.1"/>
                    <measurement group_id="B2" value="168" spread="7.6"/>
                    <measurement group_id="B3" value="167" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="11.9"/>
                    <measurement group_id="B2" value="72" spread="10.7"/>
                    <measurement group_id="B3" value="71" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m2)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="3.1"/>
                    <measurement group_id="B2" value="25" spread="3.3"/>
                    <measurement group_id="B3" value="25" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>A1C (%)</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" spread="1.6"/>
                    <measurement group_id="B2" value="10" spread="1.2"/>
                    <measurement group_id="B3" value="10" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Target</title>
        <description>length of time to achieve target glucose range using Self-Monitoring Blood Glucose (SMBG), as reference method, with the 722 Paradigm Real-Time insulin pump versus Multiple Daily Injection</description>
        <time_frame>Up to 14 days in hospital</time_frame>
        <population>subjects included in final analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Pump</title>
            <description>Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring</description>
          </group>
          <group group_id="O2">
            <title>Multiple Daily Injections</title>
            <description>Multiple daily insulin injections used for treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Target</title>
          <description>length of time to achieve target glucose range using Self-Monitoring Blood Glucose (SMBG), as reference method, with the 722 Paradigm Real-Time insulin pump versus Multiple Daily Injection</description>
          <population>subjects included in final analysis</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.1"/>
                    <measurement group_id="O2" value="6.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemic Variability</title>
        <description>Glycemic variability (mean amplitude glycemic excursion) using CGM as reference method</description>
        <time_frame>Up to 14 days in hospital</time_frame>
        <population>subjects incluced in final analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Pump</title>
            <description>Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring</description>
          </group>
          <group group_id="O2">
            <title>Multiple Daily Injections</title>
            <description>Multiple daily insulin injections used for treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Variability</title>
          <description>Glycemic variability (mean amplitude glycemic excursion) using CGM as reference method</description>
          <population>subjects incluced in final analysis</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" spread="1.89"/>
                    <measurement group_id="O2" value="3.44" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 14 days in hospital</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pump</title>
          <description>Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring</description>
        </group>
        <group group_id="E2">
          <title>Multiple Daily Injections</title>
          <description>Multiple daily insulin injections used for treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>allergic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Shin, PhD</name_or_title>
      <organization>Medtronic Diabetes</organization>
      <phone>818-576-4019</phone>
      <email>john.shin@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

